Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Belgium
/
Pharmaceuticals & Biotech
/
UCB
UCB
UCB
Rising US Price Cuts And Patent Losses Will Shadow Rewards
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 18 Analysts
Published
07 Jun 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
€166.32
16.8% overvalued
intrinsic discount
09 Aug
€194.30
Loading
1Y
26.7%
7D
5.3%
Author's Valuation
€166.3
16.8% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
€166.3
16.8% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
8b
2014
2017
2020
2023
2025
2026
2028
Revenue €7.7b
Earnings €1.5b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
10.14%
Pharma revenue growth rate
1.09%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.97%
Calculation
€1.49b
Earnings '28
x
25.17x
PE Ratio '28
=
€37.61b
Market Cap '28
€37.61b
Market Cap '28
/
190.83m
No. shares '28
=
€197.07
Share Price '28
€197.07
Share Price '28
Discounted to 2025 @ 5.97% p.a.
=
€165.60
Fair Value '25